SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

エソテリック検査市場 : 2029年までの世界予測

Esoteric Testing Market - Global Forecast To 2029

エソテリック検査市場 : タイプ（内分泌学、腫瘍学、神経学、遺伝子検査、自己免疫、感染症）、テクノロジー（ELISA、CLIA、フローサイトメトリー、NGS、RT-PCR、クロマトグラフィー、分光法）、検体（血液、尿）市場規模、トレンド・シェア - 2029年までの世界予測
Esoteric Testing Market Size, Share & Trends by Type (Endocrinology, Oncology, Neurology, Genetic Tests, Autoimmune, Infectious Diseases), Technology (ELISA, CLIA, Flow Cytometry, NGS, RT-PCR, Chromatography, Spectrometry), Specimen (Blood, Urine) - Global Forecast to 2029
出版年月2024年6月
ページ数295
図表数321
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

The global esoteric testing market is valued at an estimated USD 32.2 billion in 2024 and is projected to reach USD 48.3 billion by 2029, at a CAGR of 8.5% during the forecast period.

世界のエソテリック検査市場は、2024 年に推定 322 億米ドルと評価され、予測期間中に 8.5% の CAGR で、2029 年までに 483 億米ドルに達すると予測されています。

Growth in the esoteric testing market is primarily driven by the increasing prevalence of chronic and infectious diseases, advancements in esoteric tests for personalized medicine, and increasing research funding for precision medicine.

エソテリック検査市場 : 2029年までの世界予測

“The Oncology testing segment accounted for the highest CAGR of the esoteric testing market in 2023, by type”
Based on type, the esoteric testing market is segmented into infectious disease testing, autoimmune disease testing, endocrinology testing, oncology testing, genetic testing, toxicology and drug monitoring testing, neurology testing, and other types of testing. Esoteric oncology tests are used to determine the hereditary risk of cancer and are essential in diagnosis, prognosis, and treatment decisions. The growth of the oncology testing segment is driven by the rising prevalence of cancer and the increased adoption of various esoteric tests.

“The chemiluminescence immunoassay (CLIA) segment is projected to witness highest growth rate in the esoteric testing market, by technology, during the forecast period.”
The esoteric testing market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), real-time PCR, chromatography and mass spectrometry, flow cytometry, DNA sequencing and next-generation sequencing, and other technologies, based on technology . Growth in the number of specialized diagnostic laboratories equipped with advanced CLIA technology and the need for early diagnosis have necessitated the use of CLIA tests across the globe. Aggressive R&D expenditures by players and the development of innovative technologies such as chemiluminescent biochips, multiplexed assays, and portable immunoassays are also expected to support the growth of the CLIAs market in the coming years.

エソテリック検査市場 : 2029年までの世界予測 ecosystem

“The blood, serum, and plasma segment accounted for the largest market share of esoteric testing market, in 2023, by specimen”
Based on specimens, the esoteric testing market is segmented into blood, serum, and plasma, urine, and other specimens. The large share of this segment is attributed to the growing number of blood donations globally and the increasing incidence of chronic & infectious diseases worldwide.The use of blood as a specimen in esoteric testing is driven by its minimally invasive nature, comprehensive biomarker potential, and technological advancements. These factors, coupled with the growing emphasis on personalized medicine, regulatory support, and the need for efficient infectious disease testing, are propelling the growth of blood-based esoteric tests.

“The independent & reference laboratories segment accounted for the largest share of the esoteric testing market in 2023, by end user”.
Based on end users, the esoteric testing market is segmented into independent & reference laboratories and hospital-based laboratories. The demand for personalized medicine, the increasing prevalence of chronic and genetic diseases, and the need for cost-effective and efficient diagnostic solutions are key growth factors driving the importance of reference laboratories operating in the esoteric testing market in the coming years.

“The Asia Pacific region is projected to witness highest growth rate in the esoteric testing market during the forecast period”
The global esoteric testing market is segmented into six regions – North America, Europe, Latin America, Asia Pacific, the Middle East & Africa, and the GCC Countries. The Asia Pacific market, which comprises Japan, Australia, India, China, and the Rest of Asia Pacific, is expected to offer significant growth opportunities to market players and is projected to register the highest CAGR in the esoteric testing market during the forecast period. Government efforts to increase awareness about early disease detection and regular health checkups, rising healthcare expenditure, and the increasing number of hospitals and clinical diagnostic laboratories, and growing awareness regarding the use of esoteric tests among physicians are some of the major factors driving the growth of the esoteric testing market in the Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 45%, Tier 2 – 38%, and Tier 3 – 17%
• By Designation: C-level – 24%, D-level – 32%, and Others – 44%
• By Region: North America – 35%, Europe – 26%, Asia Pacific – 24%, Latin America – 12%, Middle East & Africa – 1%, and the GCC Countries – 2%

エソテリック検査市場 : 2029年までの世界予測 region

Lists of Companies Profiled in the Report:
Quest Diagnostics (US), Labcorp (US), H.U. Group Holdings, Inc. (Japan), Sonic Healthcare (Australia), OPKO Health, Inc. (US), Myriad Genetics, Inc. (US), The Mayo Foundation for Medical Education and Research (MFMER) (US), Eurofins Scientific (Luxembourg), Stanford Health Care (US), Foundation Medicine, Inc. (US), Kindstar Globalgene Technology, Inc. (China), Georgia Esoteric & Molecular Laboratory, LLC (US), Thyrocare Technologies Ltd. (India), ACM Global Laboratories (US), NMS Labs (US), HealthQuest Esoterics (US), Cerba Research (US), LeoLabs (India), Flow Health (US), Invitae Corporation (US), ARUP Laboratories (US), Fulgent Genetics (US), bioMONTR Labs (US), and LabGenomics (South Korea).

Research Coverage:
In this report, the esoteric testing market has been categorized based on technology (enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), real-time PCR, flow cytometry, DNA sequencing and next-generation sequencing, chromatography and mass spectrometry, and other technologies), type (oncology testing, infectious disease testing, autoimmune disease testing, genetic testing, endocrinology testing, toxicology and drug monitoring testing, neurology testing, and other types of testing), specimen (blood, serum, and plasma, urine, and other specimens) end user (independent & reference laboratories and hospital-based laboratories), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).
The report’s coverage includes comprehensive details about the key factors impacting the growth of the esoteric testing market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions and partnerships, service launches, and recent developments related to the esoteric testing market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging esoteric testing startups.

Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall esoteric testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, trends, and opportunities.

The report provides insights on the following pointers:
• Analysis of key drivers: (Advancements in esoteric tests for personalized medicine, increasing research funding for precision medicine, genetic analysis, and personalized medicine, growing number of collaborations), challenges (Dearth of skilled professionals and inaccuracies and misdiagnosis in diagnostic testing), opportunities (Emerging technologies and advanced tests for screening and risk identification in esoteric testing, and advances in understanding heterogeneity of diseases and safety signals), and restraints (Inadequate reimbursement, high capital investments and low-cost-benefit ratio for biomarkers) influencing the growth of the in esoteric testing market.
• Service Development/Innovation: Detailed insights on research & development activities and new service launches in the esoteric testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the esoteric testing market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the esoteric testing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Quest Diagnostics (US), LabCorp (US), and H.U. Group Holdings, Inc. (Japan), among others, in the esoteric testing market strategies.

Table of Contents

1            INTRODUCTION            37

1.1         STUDY OBJECTIVES      37

1.2         MARKET DEFINITION   37

1.2.1      INCLUSIONS & EXCLUSIONS OF STUDY 38

1.3         MARKET SEGMENTATION         38

1.3.1      MARKETS COVERED     38

FIGURE 1           ESOTERIC TESTING MARKET SEGMENTATION 38

1.3.2      REGIONS COVERED      39

1.3.3      YEARS CONSIDERED     39

1.4         CURRENCY        40

1.5         STAKEHOLDERS            40

1.6         SUMMARY OF CHANGES            40

1.6.1      RECESSION IMPACT      41

2            RESEARCH METHODOLOGY     42

2.1         RESEARCH DATA           42

FIGURE 2           ESOTERIC TESTING MARKET: RESEARCH DESIGN          42

2.1.1      SECONDARY DATA       43

2.1.1.1   Key data from secondary sources     44

2.1.2      PRIMARY DATA 44

2.1.2.1   Primary sources   45

2.1.2.2   Key data from primary sources         45

2.1.2.3   Key industry insights          47

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 47

FIGURE 4           BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION  48

2.2         MARKET SIZE ESTIMATION       48

2.2.1      BOTTOM-UP APPROACH           48

2.2.1.1   Approach 1: Company Revenue Estimation Approach 49

FIGURE 5           COMPANY REVENUE ESTIMATION        49

FIGURE 6           CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   50

2.2.2      TOP-DOWN APPROACH             51

FIGURE 7           ESOTERIC TESTING MARKET: TOP-DOWN APPROACH 51

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    52

FIGURE 8           DATA TRIANGULATION METHODOLOGY         52

2.4         MARKET SHARE ANALYSIS         53

2.5         STUDY ASSUMPTIONS  53

2.6         GROWTH RATE ASSUMPTIONS 53

2.7         RESEARCH LIMITATIONS           54

2.7.1      METHODOLOGY-RELATED LIMITATIONS         54

2.7.2      SCOPE-RELATED LIMITATIONS             54

2.8         RISK ASSESSMENT         54

TABLE 1             RISK ASSESSMENT         54

2.9         RECESSION IMPACT ON ESOTERIC TESTING MARKET  54

3            EXECUTIVE SUMMARY 55

FIGURE 9           ESOTERIC TESTING MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)           55

FIGURE 10         ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD BILLION) 56

FIGURE 11         ESOTERIC TESTING MARKET, BY SPECIMEN, 2024 VS. 2029 (USD BILLION)           56

FIGURE 12         ESOTERIC TESTING MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)           57

FIGURE 13         GEOGRAPHICAL SNAPSHOT OF ESOTERIC TESTING MARKET              58

4            PREMIUM INSIGHTS      59

4.1         ESOTERIC TESTING MARKET OVERVIEW           59

FIGURE 14         RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET   59

4.2         ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY  AND COUNTRY (2023)           60

FIGURE 15         ELISA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC  MARKET IN 2023         60

4.3         ESOTERIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           61

FIGURE 16         CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD              61

4.4         ESOTERIC TESTING MARKET: REGIONAL MIX (2022–2029)          62

FIGURE 17         ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD       62

4.5         ESOTERIC TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS          62

FIGURE 18         DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD     62

5            MARKET OVERVIEW     63

5.1         INTRODUCTION            63

5.2         MARKET DYNAMICS     63

FIGURE 19         ESOTERIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES 63

5.2.1      DRIVERS            64

5.2.1.1   Growing geriatric population and increasing prevalence of chronic and infectious diseases 64

FIGURE 20         INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2040 (MILLION)        64

FIGURE 21         INCIDENCE OF DIABETES, BY REGION, 2021 VS. 2030 VS. 2045 (MILLION)        65

TABLE 2             GLOBAL INCIDENCE OF INFECTIOUS DISEASES             65

FIGURE 22         GERIATRIC POPULATION, BY REGION, 2022 VS. 2050 (%)              66

TABLE 3             ESOTERIC TESTS INDICATED FOR CHRONIC AND INFECTIOUS DISEASES          66

5.2.1.2   Increasing use of esoteric DNA sequencing technologies in precision medicine and early diagnosis of cancer    67

5.2.1.3   Advancements in esoteric tests for personalized medicine          68

5.2.1.4   Increasing research funding for precision medicine, genetic analysis, and personalized medicine       69

5.2.1.5   Growing number of collaborations   70

5.2.1.6   Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing    70

5.2.2      RESTRAINTS     71

5.2.2.1   Inadequate reimbursement 71

5.2.2.2   High capital investments and low-cost-benefit ratio for biomarkers         71

5.2.3      OPPORTUNITIES           72

5.2.3.1   Emerging technologies and advanced tests for screening and risk identification in esoteric testing     72

5.2.3.2   Advances in understanding heterogeneity of diseases and safety signals   73

5.2.3.3   Growth opportunities in emerging economies 73

5.2.4      CHALLENGES   74

5.2.4.1   Dearth of skilled professionals         74

5.2.4.2   Inaccuracies and misdiagnosis in diagnostic testing      75

5.3         PRICING ANALYSIS        75

TABLE 4             AVERAGE SELLING PRICE OF ESOTERIC TESTS, BY REGION              75

5.4         VALUE CHAIN ANALYSIS            76

FIGURE 23         VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES      77

5.5         SUPPLY CHAIN ANALYSIS          78

FIGURE 24         ESOTERIC TESTING MARKET: SUPPLY CHAIN ANALYSIS              78

5.6         ECOSYSTEM ANALYSIS OF ESOTERIC TESTING MARKET            79

FIGURE 25         ESOTERIC TESTING MARKET: ECOSYSTEM ANALYSIS   79

5.6.1      ROLE IN ECOSYSTEM    79

TABLE 5             ESOTERIC TESTING MARKET: ROLE IN ECOSYSTEM      79

FIGURE 26         KEY PLAYERS IN ESOTERIC TESTING MARKET ECOSYSTEM              80

5.7         REGULATORY OVERVIEW          80

5.7.1      NORTH AMERICA          81

5.7.1.1   US         81

5.7.1.2   Canada  81

5.7.2      EUROPE             81

TABLE 6             ACCREDITATION BODIES IN EUROPE   81

5.7.3      ASIA PACIFIC    83

5.7.3.1   Japan     83

5.7.3.2   India      83

5.7.3.3   China     83

5.7.4      MIDDLE EAST  83

5.7.4.1   Saudi Arabia        83

5.7.4.2   UAE      83

5.8         TECHNOLOGY ANALYSIS           83

5.8.1      KEY TECHNOLOGIES    84

5.8.1.1   Immunoassay techniques   84

5.8.2      COMPLEMENTARY TECHNOLOGIES     84

5.8.2.1   Polymerase chain reaction 84

5.8.3      ADJACENT TECHNOLOGIES      84

5.8.3.1   Mass spectrometry             84

5.8.3.2   Flow cytometry    84

TABLE 7             KEY PLAYERS OFFERING ESOTERIC TESTS WITH ADVANCED TECHNOLOGIES            85

5.9         PATENT ANALYSIS        86

FIGURE 27         PATENT ANALYSIS FOR ESOTERIC TESTING MARKET (JANUARY 2013–DECEMBER 2023)           86

5.10       KEY CONFERENCES & EVENTS IN 2024–2025       87

TABLE 8             ESOTERIC TESTING MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS,  2O24–2025 87

5.11       PORTER’S FIVE FORCES ANALYSIS         88

FIGURE 28         ESOTERIC TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS          88

TABLE 9             ESOTERIC TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS          89

5.11.1    INTENSITY OF COMPETITIVE RIVALRY 89

5.11.2    BARGAINING POWER OF SUPPLIERS     89

5.11.3    BARGAINING POWER OF BUYERS           89

5.11.4    THREAT OF SUBSTITUTES         89

5.11.5    THREAT OF NEW ENTRANTS    90

5.12       KEY STAKEHOLDERS AND BUYING CRITERIA    90

5.12.1    KEY STAKEHOLDERS IN BUYING PROCESS         90

FIGURE 29         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS       90

TABLE 10           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%) 90

5.12.2    BUYING CRITERIA         91

FIGURE 30         KEY BUYING CRITERIA FOR ESOTERIC TESTING END USERS              91

TABLE 11           KEY BUYING CRITERIA FOR ESOTERIC TESTING END USERS              91

5.13       TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS     91

5.13.1    REVENUE SHIFT IN ESOTERIC TESTING MARKET           92

5.14       INVESTMENT AND FUNDING SCENARIO            92

6            ESOTERIC TESTING MARKET, BY TECHNOLOGY            93

6.1         INTRODUCTION            94

TABLE 12           ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 94

6.2         CHEMILUMINESCENCE IMMUNOASSAY 95

6.2.1      HIGH THROUGHPUT AND REDUCED HUMAN ERROR TO DRIVE MARKET            95

TABLE 13           ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2022–2029 (USD MILLION) 95

TABLE 14           NORTH AMERICA: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022–2029 (USD MILLION)          96

TABLE 15           EUROPE: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY,  BY COUNTRY, 2022–2029 (USD MILLION)          96

TABLE 16           ASIA PACIFIC: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022–2029 (USD MILLION)          96

TABLE 17           LATIN AMERICA: ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2022–2029 (USD MILLION)          97

6.3         ENZYME-LINKED IMMUNOSORBENT ASSAY      97

6.3.1      GROWING NUMBER OF DRUG DISCOVERY ACTIVITIES TO PROPEL MARKET            97

TABLE 18           EXAMPLES OF ESOTERIC ELISA TESTS  98

TABLE 19           ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2022–2029 (USD MILLION)          98

TABLE 20           NORTH AMERICA: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022–2029 (USD MILLION)              98

TABLE 21           EUROPE: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY,  BY COUNTRY, 2022–2029 (USD MILLION)    99

TABLE 22           ASIA PACIFIC: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022–2029 (USD MILLION)              99

TABLE 23           LATIN AMERICA: ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2022–2029 (USD MILLION)              100

6.4         REAL-TIME PCR             100

6.4.1      INCREASING USE OF QPCR FOR VARIOUS DIAGNOSTIC AND RESEARCH PURPOSES TO SUPPORT MARKET GROWTH             100

TABLE 24          ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY REGION,  2022–2029 (USD MILLION)          101

TABLE 25           NORTH AMERICA: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY,  2022–2029 (USD MILLION)    101

TABLE 26           EUROPE: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY,  2022–2029 (USD MILLION)         102

TABLE 27           ASIA PACIFIC: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY,  2022–2029 (USD MILLION) 102

TABLE 28           LATIN AMERICA: ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY COUNTRY,  2022–2029 (USD MILLION)    103

6.5         DNA SEQUENCING AND NEXT-GENERATION SEQUENCING      103

6.5.1      RISING DEMAND FOR PERSONALIZED MEDICINE TO AID MARKET GROWTH          103

TABLE 29           EXAMPLES OF ESOTERIC TESTS FOR DNA SEQUENCING              104

TABLE 30           ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)              105

TABLE 31           NORTH AMERICA: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)     105

TABLE 32           EUROPE: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)          106

TABLE 33           ASIA PACIFIC: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)     106

TABLE 34           LATIN AMERICA: ESOTERIC TESTING MARKET FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)     107

6.6         FLOW CYTOMETRY       107

6.6.1      RISING PREVALENCE OF CANCER, HIV, AND HEMATOLOGIC MALIGNANCIES TO DRIVE MARKET      107

TABLE 35           ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY REGION,  2022–2029 (USD MILLION)     108

TABLE 36           NORTH AMERICA: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY,  BY COUNTRY, 2022–2029 (USD MILLION)            108

TABLE 37           EUROPE: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY,  2022–2029 (USD MILLION)            109

TABLE 38           ASIA PACIFIC: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY,  2022–2029 (USD MILLION)            109

TABLE 39           LATIN AMERICA: ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 110

6.7         CHROMATOGRAPHY AND MASS SPECTROMETRY         110

6.7.1      METHODOLOGICAL IMPROVEMENTS AND TECHNOLOGICAL INNOVATIONS TO BOOST MARKET GROWTH  110

TABLE 40           ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY,  BY REGION, 2022–2029 (USD MILLION)             111

TABLE 41           NORTH AMERICA: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 111

TABLE 42           EUROPE: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 112

TABLE 43           ASIA PACIFIC: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 112

TABLE 44           LATIN AMERICA: ESOTERIC TESTING MARKET FOR CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 113

6.8         OTHER TECHNOLOGIES            113

TABLE 45           ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION,  2022–2029 (USD MILLION)     114

TABLE 46           NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)         114

TABLE 47           EUROPE: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,  2022–2029 (USD MILLION)      115

TABLE 48           ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES,  BY COUNTRY, 2022–2029 (USD MILLION)      115

TABLE 49           LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)         116

7            ESOTERIC TESTING MARKET, BY TYPE 117

7.1         INTRODUCTION            118

TABLE 50           ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          118

7.2         ONCOLOGY TESTING   119

7.2.1      HIGH BURDEN OF CANCER TO DRIVE MARKET 119

TABLE 51           PREVALENCE OF CANCER AMONG MALES, 2022             119

TABLE 52           PREVALENCE OF CANCER AMONG FEMALES, 2022         119

TABLE 53           EXAMPLES OF ESOTERIC TESTS FOR CANCER DIAGNOSIS              120

TABLE 54           ESOTERIC ONCOLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)     121

TABLE 55           NORTH AMERICA: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         122

TABLE 56           EUROPE: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 122

TABLE 57           ASIA PACIFIC: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 123

TABLE 58           LATIN AMERICA: ESOTERIC ONCOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 123

7.3         AUTOIMMUNE DISEASE TESTING          123

7.3.1      RISING PREVALENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH        123

TABLE 59           ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)     124

TABLE 60           NORTH AMERICA: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     124

TABLE 61           EUROPE: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      125

TABLE 62           ASIA PACIFIC: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      125

TABLE 63           LATIN AMERICA: ESOTERIC AUTOIMMUNE DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         126

7.4         INFECTIOUS DISEASE TESTING 126

7.4.1      RISING PREVALENCE OF INFECTIOUS DISEASES TO AID MARKET GROWTH          126

TABLE 64           EXAMPLES OF ESOTERIC TESTS FOR INFECTIOUS DISEASES              126

TABLE 65           ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)     128

TABLE 66           NORTH AMERICA: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         128

TABLE 67           EUROPE: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         129

TABLE 68           ASIA PACIFIC: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      129

TABLE 69           LATIN AMERICA: ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      130

7.5         ENDOCRINOLOGY TESTING     130

7.5.1      INCREASING INCIDENCE OF DIABETES TO DRIVE ADOPTION OF ESOTERIC TESTS           130

TABLE 70           ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)          131

TABLE 71           NORTH AMERICA: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      131

TABLE 72           EUROPE: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 132

TABLE 73          ASIA PACIFIC: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         132

TABLE 74           LATIN AMERICA: ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      133

7.6         GENETIC TESTING        133

7.6.1      ADVANCEMENTS IN GENOMICS AND PROTEOMICS TO SUPPORT MARKET GROWTH        133

TABLE 75           ESOTERIC GENETIC TESTING MARKET, BY REGION, 2022–2029 (USD MILLION) 134

TABLE 76           NORTH AMERICA: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 134

TABLE 77          EUROPE: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          135

TABLE 78           ASIA PACIFIC: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 135

TABLE 79           LATIN AMERICA: ESOTERIC GENETIC TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 136

7.7         NEUROLOGY TESTING 136

7.7.1      INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET            136

TABLE 80           EXAMPLES OF ESOTERIC TESTS FOR NEUROLOGICAL DISORDERS       137

TABLE 81           ESOTERIC NEUROLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)     138

TABLE 82           NORTH AMERICA: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         138

TABLE 83           EUROPE: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 139

TABLE 84           ASIA PACIFIC: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 139

TABLE 85           LATIN AMERICA: ESOTERIC NEUROLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         140

7.8         TOXICOLOGY AND DRUG MONITORING TESTING        140

7.8.1      INCREASING CASES OF DRUG ABUSE AND ILLICIT DRUG CONSUMPTION TO DRIVE DEMAND FOR ESOTERIC TESTING  140

TABLE 86           ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)          141

TABLE 87           NORTH AMERICA: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)              142

TABLE 88           EUROPE: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)   142

TABLE 89           ASIA PACIFIC: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)              143

TABLE 90           LATIN AMERICA: ESOTERIC TOXICOLOGY AND DRUG MONITORING TESTING MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)              143

7.9         OTHER TYPES OF TESTING       143

TABLE 91           ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY REGION,  2022–2029 (USD MILLION)             144

TABLE 92           NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING,  BY COUNTRY, 2022–2029 (USD MILLION) 145

TABLE 93           EUROPE: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY,  2022–2029 (USD MILLION)     145

TABLE 94           ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING, BY COUNTRY,  2022–2029 (USD MILLION)             146

TABLE 95           LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER TYPES OF TESTING,  BY COUNTRY, 2022–2029 (USD MILLION) 146

8            ESOTERIC TESTING MARKET, BY SPECIMEN      147

8.1         INTRODUCTION            148

TABLE 96           ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)          148

8.2         BLOOD, SERUM, AND PLASMA 149

8.2.1      GREATER PREFERENCE AMONG HEALTHCARE PROVIDERS TO PROPEL MARKET          149

TABLE 97           ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022–2029 (USD MILLION)      150

TABLE 98           NORTH AMERICA: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)              150

TABLE 99           EUROPE: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS,  BY COUNTRY, 2022–2029 (USD MILLION)    151

TABLE 100         ASIA PACIFIC: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)              151

TABLE 101         LATIN AMERICA: ESOTERIC TESTING MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)              152

8.3         URINE  152

8.3.1      INCREASING UTILIZATION IN ILLICIT DRUG TESTING TO BOOST DEMAND           152

TABLE 102         ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY REGION,  2022–2029 (USD MILLION)     153

TABLE 103         NORTH AMERICA: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)   153

TABLE 104        EUROPE: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY,  2022–2029 (USD MILLION)         154

TABLE 105         ASIA PACIFIC: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY,  2022–2029 (USD MILLION) 154

TABLE 106         LATIN AMERICA: ESOTERIC TESTING MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)   155

8.4         OTHER SPECIMENS       155

TABLE 107         ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY REGION,  2022–2029 (USD MILLION)     156

TABLE 108         NORTH AMERICA: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)   156

TABLE 109         EUROPE: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY,  2022–2029 (USD MILLION) 157

TABLE 110         ASIA PACIFIC: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY,  2022–2029 (USD MILLION) 157

TABLE 111         LATIN AMERICA: ESOTERIC TESTING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)   158

9            ESOTERIC TESTING MARKET, BY END USER      159

9.1         INTRODUCTION            160

TABLE 112         ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)          160

9.2         INDEPENDENT AND REFERENCE LABORATORIES          160

9.2.1      LARGEST AND FASTEST-GROWING END USERS OF ESOTERIC TESTS              160

TABLE 113         ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES,  BY REGION, 2022–2029 (USD MILLION)   161

TABLE 114         NORTH AMERICA: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 161

TABLE 115         EUROPE: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              162

TABLE 116         ASIA PACIFIC: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 162

TABLE 117         LATIN AMERICA: ESOTERIC TESTING MARKET FOR INDEPENDENT AND REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 163

9.3         HOSPITAL-BASED LABORATORIES        163

9.3.1      INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO SUPPORT MARKET GROWTH 163

TABLE 118         ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES,  BY REGION, 2022–2029 (USD MILLION)           164

TABLE 119         NORTH AMERICA: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES,  BY COUNTRY, 2022–2029 (USD MILLION)              164

TABLE 120         EUROPE: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES,  BY COUNTRY, 2022–2029 (USD MILLION)       165

TABLE 121         ASIA PACIFIC: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES,  BY COUNTRY, 2022–2029 (USD MILLION)        165

TABLE 122         LATIN AMERICA: ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES,  BY COUNTRY, 2022–2029 (USD MILLION)              166

10          ESOTERIC TESTING MARKET, BY REGION          167

10.1       INTRODUCTION            168

TABLE 123         ESOTERIC TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)          168

10.2       NORTH AMERICA          169

FIGURE 31         NORTH AMERICA: ESOTERIC TESTING MARKET SNAPSHOT              170

TABLE 124         NORTH AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          171

TABLE 125         NORTH AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          171

TABLE 126         NORTH AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       172

TABLE 127        NORTH AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN,  2022–2029 (USD MILLION)          172

TABLE 128         NORTH AMERICA: ESOTERIC TESTING MARKET, BY END USER,  2022–2029 (USD MILLION)          173

10.2.1    NORTH AMERICA: RECESSION IMPACT 173

10.2.2    US         173

10.2.2.1 Favorable policies for molecular diagnostic providers to support market growth              173

TABLE 129         US: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022         174

TABLE 130         US: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          175

TABLE 131         US: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 175

TABLE 132         US: ESOTERIC TESTING MARKET, BY SPECIMEN,  2022–2029 (USD MILLION) 176

TABLE 133         US: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 176

10.2.3    CANADA            176

10.2.3.1 Lack of proper reimbursements for diagnostic tests to hamper market growth              176

TABLE 134         CANADA: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 178

TABLE 135         CANADA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          178

TABLE 136         CANADA: ESOTERIC TESTING MARKET, BY SPECIMEN,  2022–2029 (USD MILLION)     179

TABLE 137         CANADA: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     179

10.3       EUROPE             179

TABLE 138         EUROPE: ESOTERIC TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     180

TABLE 139         EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 181

TABLE 140         EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          181

TABLE 141         EUROPE: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)     182

TABLE 142         EUROPE: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     182

10.3.1    EUROPE: RECESSION IMPACT   182

10.3.2    GERMANY         183

10.3.2.1 Favorable government policies to propel market          183

TABLE 143         GERMANY: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022       183

TABLE 144         GERMANY: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 184

TABLE 145         GERMANY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          184

TABLE 146         GERMANY: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)     185

TABLE 147         GERMANY: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     185

10.3.3    FRANCE             185

10.3.3.1 Rising demand for early disease diagnosis to drive market          185

TABLE 148         FRANCE: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 186

TABLE 149         FRANCE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          186

TABLE 150         FRANCE: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)     187

TABLE 151         FRANCE: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     187

10.3.4    ITALY   187

10.3.4.1 Rapidly growing geriatric population to favor market growth     187

TABLE 152         ITALY: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          188

TABLE 153         ITALY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     189

TABLE 154         ITALY: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 189

TABLE 155         ITALY: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 190

10.3.5    UK         190

10.3.5.1 Favorable investment scenario to drive market             190

TABLE 156         UK: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          191

TABLE 157         UK: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 191

TABLE 158         UK: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 192

TABLE 159         UK: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 192

10.3.6    SPAIN   192

10.3.6.1 High burden of chronic and infectious diseases to drive adoption of esoteric tests              192

TABLE 160         SPAIN: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          193

TABLE 161         SPAIN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     194

TABLE 162         SPAIN: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 194

TABLE 163         SPAIN: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 195

10.3.7    REST OF EUROPE           195

TABLE 164         REST OF EUROPE: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045      196

TABLE 165         REST OF EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          196

TABLE 166         REST OF EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       197

TABLE 167         REST OF EUROPE: ESOTERIC TESTING MARKET, BY SPECIMEN,  2022–2029 (USD MILLION)          197

TABLE 168         REST OF EUROPE: ESOTERIC TESTING MARKET, BY END USER,  2022–2029 (USD MILLION)          198

10.4       ASIA PACIFIC    198

FIGURE 32         ASIA PACIFIC: ESOTERIC TESTING MARKET SNAPSHOT              199

TABLE 169         ASIA PACIFIC: ESOTERIC TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          200

TABLE 170         ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)     200

TABLE 171        ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          201

TABLE 172         ASIA PACIFIC: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)          201

TABLE 173         ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)          202

10.4.1    ASIA PACIFIC: RECESSION IMPACT        202

10.4.2    JAPAN  202

10.4.2.1 Presence of well-developed healthcare system to favor market growth      202

TABLE 174         JAPAN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 203

TABLE 175         JAPAN: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          203

TABLE 176         JAPAN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     204

TABLE 177         JAPAN: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 204

TABLE 178         JAPAN: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 205

10.4.3    CHINA  205

10.4.3.1 China to register highest growth rate in Asia Pacific esoteric testing market during forecast period     205

TABLE 179         CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 206

TABLE 180         CHINA: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          206

TABLE 181         CHINA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     207

TABLE 182         CHINA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 207

TABLE 183         CHINA: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 208

10.4.4    INDIA   208

10.4.4.1 Improving healthcare system to support market growth             208

TABLE 184         INDIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 208

TABLE 185         INDIA: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          209

TABLE 186         INDIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     210

TABLE 187         INDIA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 210

TABLE 188         INDIA: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 211

10.4.5    AUSTRALIA       211

10.4.5.1 Increasing incidence of chronic diseases and increasing focus on preventive healthcare to propel market             211

TABLE 189         AUSTRALIA: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 212

TABLE 190         AUSTRALIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          212

TABLE 191         AUSTRALIA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)     213

TABLE 192         AUSTRALIA: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     213

10.4.6    REST OF ASIA PACIFIC  213

TABLE 193         REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)          214

TABLE 194         REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       215

TABLE 195         REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY SPECIMEN,  2022–2029 (USD MILLION) 215

TABLE 196         REST OF ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER,  2022–2029 (USD MILLION)          216

10.5       LATIN AMERICA             216

TABLE 197         LATIN AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          217

TABLE 198         LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)     217

TABLE 199         LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       218

TABLE 200         LATIN AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)          218

TABLE 201         LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)          219

10.5.1    LATIN AMERICA: RECESSION IMPACT   219

10.5.2    BRAZIL 219

10.5.2.1 Presence of large and well-developed pharmaceutical industry to drive market              219

TABLE 202         BRAZIL: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 220

TABLE 203         BRAZIL: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     221

TABLE 204         BRAZIL: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 221

TABLE 205         BRAZIL: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 222

10.5.3    MEXICO             222

10.5.3.1 Growth in private healthcare sector to propel market   222

TABLE 206         MEXICO: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION) 223

TABLE 207         MEXICO: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          223

TABLE 208         MEXICO: ESOTERIC TESTING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)     224

TABLE 209         MEXICO: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     224

10.5.4    REST OF LATIN AMERICA          224

TABLE 210         REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE,  2022–2029 (USD MILLION)          225

TABLE 211         REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       226

TABLE 212         REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY SPECIMEN,  2022–2029 (USD MILLION) 226

TABLE 213         REST OF LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER,  2022–2029 (USD MILLION) 227

10.6       MIDDLE EAST & AFRICA             227

10.6.1    IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET            227

TABLE 214        AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 228

TABLE 215         MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY TEST,  2022–2029 (USD MILLION)          228

TABLE 216         MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       229

TABLE 217         MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY SPECIMEN,  2022–2029 (USD MILLION) 229

TABLE 218         MIDDLE EAST & AFRICA: ESOTERIC TESTING MARKET, BY END USER,  2022–2029 (USD MILLION)          230

10.7       MIDDLE EAST & AFRICA: RECESSION IMPACT   230

10.8       GCC COUNTRIES           230

10.8.1    HEALTHCARE INFRASTRUCTURE DEVELOPMENT TO DRIVE MARKET              230

TABLE 219         GCC COUNTRIES: ESOTERIC TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)     231

TABLE 220         GCC COUNTRIES: ESOTERIC TESTING MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       232

TABLE 221         GCC COUNTRIES: ESOTERIC TESTING MARKET, BY SPECIMEN,  2022–2029 (USD MILLION)          232

TABLE 222         GCC COUNTRIES: ESOTERIC TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)          233

10.8.2    GCC COUNTRIES: RECESSION IMPACT 233

11          COMPETITIVE LANDSCAPE       234

11.1       OVERVIEW        234

11.2       KEY PLAYER STRATEGIES/RIGHT TO WIN          234

TABLE 223         OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS           234

11.3       REVENUE SHARE ANALYSIS       236

FIGURE 33         REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ESOTERIC TESTING MARKET, 2021–2023 (USD MILLION)   236

11.4       MARKET SHARE ANALYSIS         237

TABLE 224         ESOTERIC TESTING MARKET: DEGREE OF COMPETITION              237

FIGURE 34         ESOTERIC TESTING MARKET SHARE ANALYSIS, 2023     238

11.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   239

11.5.1    STARS  239

11.5.2    EMERGING LEADERS    239

11.5.3    PERVASIVE PLAYERS     239

11.5.4    PARTICIPANTS 240

FIGURE 35         ESOTERIC TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023    240

11.5.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      241

TABLE 225         COMPANY FOOTPRINT 241

TABLE 226         TYPE FOOTPRINT         242

TABLE 227         TECHNOLOGY FOOTPRINT      243

TABLE 228         END-USER FOOTPRINT 243

TABLE 229         REGIONAL FOOTPRINT             244

11.6       COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023          245

11.6.1    PROGRESSIVE COMPANIES       245

11.6.2    STARTING BLOCKS       245

11.6.3    RESPONSIVE COMPANIES          245

11.6.4    DYNAMIC COMPANIES 245

FIGURE 36         ESOTERIC TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023           246

11.6.5    COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES         247

TABLE 230         ESOTERIC TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES           247

11.7       COMPETITIVE SCENARIO          247

11.7.1    SERVICE LAUNCHES     247

TABLE 231         ESOTERIC TESTING MARKET: SERVICE LAUNCHES, JANUARY 2021–APRIL 2024             247

11.7.2    DEALS  248

TABLE 232         ESOTERIC TESTING MARKET: DEALS, JANUARY 2021–APRIL 2024      248

11.7.3    EXPANSIONS    249

TABLE 233         ESOTERIC TESTING MARKET: EXPANSIONS, JANUARY 2021–APRIL 2024        249

11.8       VALUATION AND FINANCIAL METRICS OF ESOTERIC TESTING VENDORS          250

FIGURE 37         EV/EBITDA OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET            250

FIGURE 38         EV/REVENUE OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET            250

FIGURE 39         1-YEAR PRICE TOTAL RETURN OF TOP 3 COMPANIES IN ESOTERIC  TESTING MARKET 251

FIGURE 40         5-YEAR BETA OF TOP 3 COMPANIES IN ESOTERIC TESTING MARKET            251

12          COMPANY PROFILES    252

(Business overview, Products offered, Recent Developments, MNM view)*

12.1       MAJOR PLAYERS            252

12.1.1    LABCORP          252

TABLE 234         LABCORP: BUSINESS OVERVIEW            252

FIGURE 41         LABCORP: COMPANY SNAPSHOT (2023)             252

TABLE 235         LABCORP: SERVICES OFFERED 253

TABLE 236         LABCORP: SERVICE LAUNCHES, JANUARY 2021–APRIL 2024              254

TABLE 237         LABCORP: DEALS, JANUARY 2021–APRIL 2024    255

TABLE 238         LABCORP: EXPANSIONS, JANUARY 2021–APRIL 2024       256

12.1.2    QUEST DIAGNOSTICS   258

TABLE 239         QUEST DIAGNOSTICS: BUSINESS OVERVIEW     258

FIGURE 42         QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2023)     259

TABLE 240         QUEST DIAGNOSTICS: SERVICES OFFERED       259

TABLE 241         QUEST DIAGNOSTICS: SERVICE LAUNCHES, JANUARY 2021–APRIL 2024        262

TABLE 242         QUEST DIAGNOSTICS: DEALS, JANUARY 2021–APRIL 2024              262

TABLE 243         QUEST DIAGNOSTICS: EXPANSIONS, JANUARY 2021–APRIL 2024      264

12.1.3    OPKO HEALTH, INC.     265

TABLE 244         OPKO HEALTH, INC.: BUSINESS OVERVIEW       265

FIGURE 43         OPKO HEALTH, INC.: COMPANY SNAPSHOT (2023)        266

TABLE 245         OPKO HEALTH, INC.: SERVICES OFFERED          266

TABLE 246         OPKO HEALTH, INC.: DEALS, JANUARY 2021–APRIL 2024              267

12.1.4    H.U. GROUP HOLDINGS, INC.    269

TABLE 247         H.U. GROUP HOLDINGS, INC.: BUSINESS OVERVIEW      269

FIGURE 44         H.U. GROUP HOLDINGS, INC.: COMPANY SNAPSHOT (2023)              269

TABLE 248         H.U. GROUP HOLDINGS, INC.: SERVICES OFFERED        270

TABLE 249         H.U. GROUP HOLDINGS, INC.: DEALS, JANUARY 2021–APRIL 2024      270

12.1.5    SONIC HEALTHCARE LIMITED 271

TABLE 250         SONIC HEALTHCARE LIMITED: BUSINESS OVERVIEW   271

FIGURE 45         SONIC HEALTHCARE LIMITED: COMPANY SNAPSHOT (2023)              272

TABLE 251         SONIC HEALTHCARE LIMITED: SERVICES OFFERED      272

TABLE 252         SONIC HEALTHCARE LIMITED: DEALS 273

12.1.6    MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER)           274

TABLE 253         MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: BUSINESS OVERVIEW          274

TABLE 254         MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: SERVICES OFFERED             274

12.1.7    EUROFINS SCIENTIFIC  275

TABLE 255         EUROFINS SCIENTIFIC: BUSINESS OVERVIEW    275

FIGURE 46         EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)    276

TABLE 256         EUROFINS SCIENTIFIC: SERVICES OFFERED      276

TABLE 257         EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021–APRIL 2024        277

TABLE 258         EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–APRIL 2024              277

12.1.8    STANFORD HEALTH CARE        278

TABLE 259         STANFORD HEALTH CARE: BUSINESS OVERVIEW           278

TABLE 260         STANFORD HEALTH CARE: SERVICES OFFERED 278

TABLE 261         STANFORD HEALTH CARE: SERVICE LAUNCHES, JANUARY 2021–APRIL 2024             278

TABLE 262         STANFORD HEALTH CARE: DEALS, JANUARY 2021–APRIL 2024              279

12.1.9    FOUNDATION MEDICINE, INC. 280

TABLE 263         FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW   280

TABLE 264         FOUNDATION MEDICINE, INC.: SERVICES OFFERED      280

TABLE 265         FOUNDATION MEDICINE, INC.: DEALS, JANUARY 2021–APRIL 2024      281

12.1.10  KINDSTAR GLOBALGENE TECHNOLOGY, INC.  282

TABLE 266         KINDSTAR GLOBALGENE TECHNOLOGY, INC.: BUSINESS OVERVIEW        282

FIGURE 47         KINDSTAR GLOBALGENE TECHNOLOGY, INC.: COMPANY SNAPSHOT (2023)          282

TABLE 267         KINDSTAR GLOBALGENE TECHNOLOGY, INC.: SERVICES OFFERED          283

12.1.11  GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC             284

TABLE 268         GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: BUSINESS OVERVIEW    284

TABLE 269         GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: SERVICES OFFERED      284

12.1.12  THYROCARE TECHNOLOGIES LIMITED 285

TABLE 270         THYROCARE TECHNOLOGIES LIMITED: BUSINESS OVERVIEW              285

FIGURE 48         THYROCARE TECHNOLOGIES LIMITED: COMPANY SNAPSHOT (2023)   285

TABLE 271         THYROCARE TECHNOLOGIES LIMITED: SERVICES OFFERED              286

12.1.13  ACM GLOBAL LABORATORIES  287

TABLE 272         ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW    287

TABLE 273         ACM GLOBAL LABORATORIES: SERVICES OFFERED       287

12.2       OTHER PLAYERS           288

12.2.1    NMS LABS          288

12.2.2    HEALTHQUEST ESOTERICS       288

12.2.3    CERBA XPERT   289

12.2.4    LEOLABS, INC.  290

12.2.5    FLOW HEALTH 290

12.2.6    INVITAE CORPORATION            291

12.2.7    MYRIAD GENETICS, INC.            292

12.2.8    ARUP LABORATORIES  293

12.2.9    FULGENT GENETICS    294

12.2.10  BIOMONTR LABS           295

12.2.11  LABGENOMICS 295

*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13          APPENDIX         296

13.1       DISCUSSION GUIDE      296

13.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             300

13.3       CUSTOMIZATION OPTIONS      302

13.4       RELATED REPORTS       303

13.5       AUTHOR DETAILS         304

医療・医薬の最新記事8件